Format

Send to

Choose Destination
See comment in PubMed Commons below
Proteomics Clin Appl. 2010 Mar;4(3):304-14. doi: 10.1002/prca.200900042. Epub 2010 Jan 4.

Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis.

Author information

1
Department of Gynaecology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. alpetri@dadlnet.dk

Abstract

PURPOSE:

The purposes of this study were to confirm previously found candidate epithelial ovarian cancer biomarkers in urine and to compare a paired serum biomarker panel and a urine biomarker panel from the same study cohort with regard to the receiver operating characteristic curve (ROC) area under the ROC curve (AUC) values.

EXPERIMENTAL DESIGN:

Four significant urine biomarkers were confirmed among 130 pelvic mass patients in the present study. The four biomarkers form a potential urine biomarker panel. From the same study cohort, the potential urine biomarker panel was compared to a serum biomarker panel, consisting of seven proteins/peptides, OvaRI.

RESULTS:

Multivariate analysis of the urine panel demonstrated a significant differentiation (p<0.0001) between epithelial ovarian cancer patients and patients with benign ovarian pelvic masses. The ROC AUC of the urine panel was 0.84 and the ROC AUC of OvaRI was 0.83. Combining the urine panel with OvaRI demonstrated a significant contribution from both, for urine peaks, OR=2.12 and for OvaRI, OR=1.39; the ROC AUC of this model was 0.88.

CONCLUSIONS AND CLINICAL RELEVANCE:

We demonstrated that both urine and serum can be used individually or in combination to potentially aid in ovarian cancer diagnostics. Urine proteomic profiling could provide biomarkers for the non-invasive test required in clinical practice.

PMID:
21137051
DOI:
10.1002/prca.200900042
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center